Drugs / QL0911
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT06456528 | Oct 2024 → Jul 2026 overdue | thrombocytopenia | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05554913 | Nov 2022 → Feb 2024 | thrombocytopenia | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT05851027 | Jan → Sep 2021 | thrombocytopenia | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07455006 | Apr 2026 → Dec 2027 expected | thrombocytopenia due to immune destruction | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05621330 | Oct 2019 → Dec 2021 | autoimmune thrombocytopenia | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL0911 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05851027 ↗ |
| Action | Activate | “thrombopoietin mimetic” NCT05621330 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Thrombopoietin Mimetic Peptide-Fc Fusion Protein” NCT05554913 ↗ |
| Route | Subcutaneous | “as a subcutaneous injection” NCT05554913 ↗ |